相关实验视频

Updated: Sep 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

在mHSPC中对恩扎胺与达罗胺双剂进行匹配调整后的间接比较

Andrew J Armstrong¹, Bhavik J Pandya², Hemant Singh Bhadauria²

¹Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.

Future oncology (London, England)

|July 14, 2025

概括

在治疗转移性激素敏感前列腺癌 (mHSPC) 时,恩扎胺加上安德罗基因剥夺疗法 (ADT) 显示出比达罗胺加上ADT更高的疗效. 这一发现支持恩扎胺作为mHSPC患者首选的治疗选择.

科学领域:

在瘤学瘤学.
临床药理学临床药理学

背景情况:

转移性激素敏感前列腺癌 (mHSPC) 需要有效的治疗策略.
雄激素剥夺疗法 (ADT) 是mHSPC管理的基石.
新的激素药物,如恩扎胺和达罗胺,与ADT结合使用.

研究的目的:

在mHSPC患者中比较恩扎胺+ADT与达罗胺+ADT的疗效.
进行匹配调整的间接比较 (MAIC) 来评估治疗结果.
为了提供证据,在mHSPC治疗中做出明智的临床决策.

主要方法:

使用了来自ARCHES试验 (甲胺+ADT) 的个体患者数据.
权重和调整数据以匹配ARANOTE试验 (达洛胺 + ADT) 的总结基线特征.
采用了基于安慰剂+ADT的MAIC来导出治疗比较的危险比率.

主要成果:

与达罗胺 + ADT 相比,恩扎胺 + ADT显著改善了无放射性进展的生存率 (HR:0.54;p=0.03) 和达到割抵抗的时间 (HR:0.57;p=0.03).
趋势有利于对前列腺特异性抗原进展的时间和新抗瘤治疗的时间,尽管在统计学上不显著.
该MAIC分析包括319名患者的有效样本大小.

结论:

在治疗mHSPC时,恩扎胺 + ADT与达罗胺 + ADT相比,表现出更高的疗效.
这些发现为优化mHSPC治疗策略提供了宝贵的见解.
这项研究支持使用恩扎拉胺+ADT,以改善mHSPC的结果.

关键词:

雄激素受体通路抑制剂达洛胺胺的使用方法酵素胺胺的使用方法间接治疗比较间接治疗比较转移性荷尔蒙敏感的前列腺癌

更多相关视频

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...